Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 23.97% and Operating profit at 20.51% over the last 5 years
2
The company has declared Negative results for the last 3 consecutive quarters
3
With ROE of 9.68%, it has a very expensive valuation with a 4.69 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 30,083 Million (Large Cap)
45.00
NA
0.47%
0.14
10.61%
4.65
Revenue and Profits:
Net Sales:
686 Million
(Quarterly Results - Mar 2026)
Net Profit:
182 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.28%
0%
14.28%
6 Months
10.55%
0%
10.55%
1 Year
52.84%
0%
52.84%
2 Years
88.3%
0%
88.3%
3 Years
8.4%
0%
8.4%
4 Years
-26.47%
0%
-26.47%
5 Years
-10.69%
0%
-10.69%
iRay Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.99%
EBIT Growth (5y)
18.57%
EBIT to Interest (avg)
48.41
Debt to EBITDA (avg)
1.01
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.24
Tax Ratio
6.14%
Dividend Payout Ratio
22.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
19.30%
ROE (avg)
13.25%
Valuation key factors
Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
4.83
EV to EBIT
51.62
EV to EBITDA
41.64
EV to Capital Employed
4.36
EV to Sales
13.10
PEG Ratio
7.71
Dividend Yield
0.46%
ROCE (Latest)
8.45%
ROE (Latest)
10.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
686.20
478.00
43.56%
Operating Profit (PBDIT) excl Other Income
161.70
168.10
-3.81%
Interest
31.40
9.20
241.30%
Exceptional Items
1.60
-0.80
300.00%
Consolidate Net Profit
182.40
135.60
34.51%
Operating Profit Margin (Excl OI)
235.70%
262.00%
-2.63%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 43.56% vs -2.63% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 34.51% vs -1.17% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,241.10
1,825.10
22.79%
Operating Profit (PBDIT) excl Other Income
786.60
487.70
61.29%
Interest
27.80
29.80
-6.71%
Exceptional Items
-11.40
-49.00
76.73%
Consolidate Net Profit
632.20
450.40
40.36%
Operating Profit Margin (Excl OI)
265.30%
216.30%
4.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 22.79% vs -1.71% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 40.36% vs -25.53% in Dec 2024
About iRay Technology Co., Ltd. 
iRay Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






